Overview
Discounted cash flow
Income / accounting-based
Multiples & assets
Scenario
Toolbox
Weighted blend
$108.04
-20.29% vs spot
Sell
Spot price
$135.54
Mkt cap $38.3B
subtle cardAnalyst PT consensus
$166.00
+22.47% vs spot
subtle cardMethods covered
18 / 19
15 in blend
subtle cardFootball field
A · fair-value range by method
Method comparison
A · fair value by valuation framework
| Method | Category | Fair value | Range | vs spot | Weight | Driver | Conf. |
|---|---|---|---|---|---|---|---|
| DCF · FCFF | dcf | $159.32 | $116.89 – $224.39 | +17.55% | 22.3% | WACC 7.6%, g₀=17.4%, gₗ=2.0% | high |
| DCF · FCFE | dcf | $104.56 | $81.84 – $136.17 | -22.86% | 16.8% | kₑ 9.9%, g₀=17.4%, gₗ=2.0% | high |
| DDM · Gordon | ddm | $15.26 | $13.54 – $17.47 | -88.75% | — | D₁ 1.18, kₑ 9.9%, gₗ 2.0% | med |
| DDM · H-model | ddm | $26.74 | $21.75 – $33.19 | -80.27% | — | D₀ 1.18, g₀=17.4%, gₗ=2.0%, H 5y | med |
| DDM · multi-stage | ddm | $21.29 | $18.10 – $24.49 | -84.29% | 5.6% | 5y schedule 17.4% → 2.0%, kₑ 9.9% | high |
| Residual income | income | $34.53 | $30.39 – $38.68 | -74.52% | 11.2% | BV 28.23, ROE 19.3% → kₑ | high |
| EVA / MVA | income | $154.23 | $135.72 – $172.74 | +13.79% | 7.8% | IC 8.3B, WACC 7.6% | high |
| P/E · sector | multiple | $100.54 | $88.48 – $112.60 | -25.82% | 13.4% | EPS 4.57 × peer P/E 22.0 | med |
| P/S · sector | multiple | $116.39 | $98.93 – $133.85 | -14.13% | 3.4% | Rev/sh 29.10 × peer P/S 4.00 | med |
| EV / EBITDA | multiple | $108.72 | $95.67 – $121.77 | -19.79% | 11.2% | EBITDA × peer 15.0× − ND 1.6B | high |
| EV / EBIT | multiple | $104.94 | $89.20 – $120.68 | -22.58% | 2.2% | EBIT × peer 18.0× − ND | med |
| EV / Sales | multiple | $92.38 | $78.52 – $106.24 | -31.84% | 2.2% | Sales × peer 3.40× − ND | med |
| PEG-anchored | multiple | $147.16 | $125.08 – $169.23 | +8.57% | 1.1% | PEG=1, fwd EPS g 32.2% | med |
| Earnings power | intrinsic | $66.79 | $58.77 – $74.80 | -50.72% | 0.6% | NOPAT / WACC, no growth | med |
| Graham revised | intrinsic | $194.89 | $165.66 – $224.13 | +43.79% | 0.6% | EPS×(8.5+2g)·4.4/Y | low |
| Lynch P/E=g | intrinsic | $79.35 | $67.45 – $91.26 | -41.45% | 0.6% | PE = g (17.4) | low |
| Book NAV | asset | $28.23 | $26.82 – $29.64 | -79.17% | 1.1% | (Assets − Liabilities) / Shares | high |
| Liquidation | asset | $14.49 | $12.32 – $16.66 | -89.31% | — | Cash 100% + non-cash 70% − Liab. | low |
| Reverse DCF | reverse | — | — | — | — | Implied g 17.5% · Aggressive — well above sector trend | high |
Cost-of-capital build-up
CAPM cost of equity, after-tax cost of debt, WACC. Risk-free as of 2026-05-12.
| Risk-free rate (US 10y Treasury)rf | 4.46% |
| Equity beta (1.22)β | × 1.22 |
| Equity risk premiumERP | 4.46% |
| Cost of equity (CAPM)kₑ | 9.90% |
| Pre-tax cost of debtkd | 3.34% |
| Effective tax ratet | 9.9% |
| After-tax cost of debt | 3.01% |
| Equity weight$6.7B | 66.8% |
| Debt weight$3.4B | 33.2% |
| WACC | 7.61% |
Growth assumptions
Blended forward growth used as DCF default; terminal pegged to long-run nominal GDP.
| Analyst forward revenue growthFMP | 7.02% |
| Analyst forward EPS growthFMP | 32.20% |
| Historical 5y revenue CAGRFY | 2.40% |
| Historical 5y EPS CAGRFY | 3.78% |
| Sustainable g (ROE × retention)Δ | 15.15% |
| Blended near-term growth (g₀) | 17.36% |
| Terminal growth (gₗ) | 2.00% |
Sources
- FMP /analyst-estimates— 8 rows(as of 2023-10-31)
- Treasury rates · 10y— 4.46% rf(as of 2026-05-12)
- market_risk_premium · DB— 4.46% ERP(as of 2026-05-13)
- Sector multiple defaults— Healthcare (live sector PE unavailable)
- FMP /price-target-consensus— mean $166.00
This page is generated by a quantitative valuation engine for research purposes only and does not constitute investment advice. Methodology follows standard CFA / Damodaran frameworks; assumptions are driven by analyst consensus from Financial Modeling Prep and reported financial statements.